Results 61 to 70 of about 15,148 (196)

Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

International Journal of Cancer, EarlyView.
ABSTRACT Approximately 6%–8% of children and adolescents with rhabdomyosarcoma (RMS) have an underlying cancer predisposition disorder (CPD), which varies between embryonal and alveolar subtypes and other clinical characteristics. Identifying a CPD remains challenging, as traditional approaches rely on clinical features and family history. Additionally,
Taylor M. Luckie, Sarah Scollon, Yao Yu, Aniko Sabo, Tiffany Chambers, Olga Taylor, Logan G. Spector, Michael E. Scheurer, Douglas S. Hawkins, Rajkumar Venkatramani, Chad D. Huff, Sharon E. Plon, Philip J. Lupo   +12 more
wiley   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Global Oil and Gas Stocks: Anomalies, Systematic Risks and Mispricing

International Journal of Finance &Economics, EarlyView.
ABSTRACT We analyse anomaly and factor risk premia in the global oil and gas (OG) sector, which plays a central role in the global economy through its importance for energy supply, industrial production, and capital markets. Using firm‐level and portfolio data, we examine whether cross‐sectional return patterns reflect systematic risk compensation or ...
Nader Virk, Mohsin Sadaqat, Hilal A. Butt, Giulia Fantini   +3 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Case Report: Discordance between RNA-identified ETV6::RET and clinically reportable DNA profiling in salivary gland secretory carcinoma

Frontiers in Oncology
Secretory carcinoma of the salivary gland is a rare, fusion-driven malignancy in which kinase fusions can serve as therapeutic targets. We report a patient with an ETV6::RET-positive tumor who achieved a complete response to pralsetinib and subsequently ...
Shogen Boku, Takao Fujisawa, Takao Fujisawa, Tomofumi Sakagami, Shigenori Kadowaki, Hironaga Satake, Hisateru Yasui, Koushiro Ohtsubo, Yasushi Shimizu, Tomoyuki Otsuka, Bunya Kuze, Riu Yamashita, Riu Yamashita, Taro Shibuki, Taro Shibuki, Yoshiaki Nakamura, Yoshiaki Nakamura, Hideaki Bando, Hideaki Bando, Takayuki Yoshino, Milan Radovich, Masao Yagi, Susumu Okano, Susumu Okano   +23 more
doaj   +1 more source

RET rearrangements are actionable alterations in breast cancer

Nature Communications, 2018
Fusions of the gene RET have been described in thyroid and lung cancers. Here, the AUs identify RET gene alterations, including known fusions, novel fusions, and rearrangements in breast cancer (BC) that are involved in the tumorigenic process and show ...
Bhavna S. Paratala, Jon H. Chung, Casey B. Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B. Schrock, Laurie M. Gay, Ellen Lee, Sonia C. Dolfi, Kien Pham, Stephanie Lin, Ming Yao, Atul Kulkarni, Frances DiClemente, Chen Liu, Lorna Rodriguez-Rodriguez, Shridar Ganesan, Jeffrey S. Ross, Siraj M. Ali, Brian Leyland-Jones, Kim M. Hirshfield   +21 more
doaj   +1 more source

Performance Measures, Discretionary Accruals, and CEO Cash Compensation

Journal of Corporate Accounting &Finance, EarlyView.
ABSTRACT This paper examines the relative weights assigned to three performance measures—stock returns, accounting earnings, and operating cash flows—in determining executive cash compensation. We find that returns receive the highest weight, followed by earnings, while cash flows carry the least weight.
Ya Dai, Harrison Liu, Jennifer Yin
wiley   +1 more source

Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report

Frontiers in Oncology
Acquired resistance remains a major challenge in RET fusion-positive non-small cell lung cancer treated with selective RET inhibitors. NTRK fusions represent a rare off-target resistance mechanism in this setting, with limited clinical data to guide ...
Ritwika Choudhury, Mansi Sharma, Abhinav Dewan, Sabeena K. Choudhary, Priyanka Venkatraman, Vivek Subbiah, Ullas Batra   +6 more
doaj   +1 more source

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma

The Laryngoscope, EarlyView.
We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Masaru Yamashita   +3 more
wiley   +1 more source

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets

Cancer Medicine
Background Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor‐agnostic manner. However, the objective response rate was the lowest among entrectinib‐
Zhaohui Liao Arter, Alexandria T. M. Lee, Misako Nagasaka, Sai‐Hong Ignatius Ou   +3 more
doaj   +1 more source